News Releases

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
LAVA-051 Phase 1/2a trial actively enrolling in hematological malignancies on track to report initial data in H1 2022 LAVA-1207 Phase 1/2a trial in metastatic castrate resistant prostate cancer on track to begin enrolling later this quarter LAVA-051 granted orphan drug designation by the U.S.
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company, today announced that LAVA and The Antibody Society , a non-profit association, are co-organizing a virtual symposium
LAVA Therapeutics Expands Management Team with Three Key Appointments
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of
LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of
LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
Paul W.H.I. Parren, Ph.D., EVP, Head of R&D to share data regarding LAVA bispecific gamma delta T cell engagers derived from proprietary Gammabody™ platform UTRECHT, The Netherlands and PHILADELPHIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.
LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s CD1d targeted
LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
UTRECHT, The Netherlands and PHILADELPHIA , Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by  LAVA Therapeutics N.V. (Nasdaq: LVTX), please note that in the second paragraph Vγ9Vδ2 T cells were incorrectly written as V9V2 T cells. The corrected release
LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant prostate cancer; on track to begin later this year Collaboration with Janssen Biotech, Inc.
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary
UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced the appointment of Amy
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia UTRECHT, The Netherlands and PHILADELPHIA, July 13, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on